Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Farmaforce
Industry Trends 2016 Forecast
Latest News
Pfizer denied in Brenzys court case
Patent Litigation: An attempt by Pfizer to set up a patent infringement case against MSD's Enbrel competitor, Brenzys - set to PBS list on 1 April - has been knocked back by the Federal Court.
Bayer's $30m win a 'new benchmark'
Damages: Bayer's $30 million award against Generic Health in the Yasmin case has set a new benchmark for damages in patent infringement cases lawyers say but warn an appeal is likely.
Three way tussle for millions of flu shots
Immunisation: As the flu season looms, the Pharmacy Guild is urging consumers to visit its members for vaccination, prominent non-member Chemist Warehouse is offering a low-price option and doctors are warning high-risk patients to give pharmacy a miss.
NZ GPs gear up to end DTC advertising
Drug Promotion: An expected revamp of New Zealand's pharma legislation this year has medical groups angling to do away with the country's near unique DTC advertising environment.
Jardiance effect extends to all SGLT-2s
New Data: A study of three SGLT-2 inhibitors has indicated that the capacity of BI's Jardiance to ward off cardiovascular death is likely to be a class effect.
Most Popular
Patient groups rate pharma
Reputation: Australian patient groups have rated pharmacos low for innovation compared to groups in other countries but not as low as NZ, while ViiV and AbbVie have topped the most reputable list.
TGA bows to industry on fast tracking
Sansom Reforms: The TGA has made changes to its expedited pathways proposal on the back of feedback from industry.
Paradigm shift in RA outcomes
Treatment Trends: New products and refined treatment regimens mean RA patients - who cost the PBS $600m a year - can soon expect to lead normal lives says the MJA.
Bayer wins $30m from Generic Health
Patent Litigation: Bayer expects to receive more than $30m from Generic Health after the Federal Court largely accepted its calculation of damages arising from infringement of its Yasmin patent.
Payments reveal companies' top docs
Transparency Reporting: Further analysis of MA members' transparency reports shows that among named HCPs, the top 250 were paid over $3 million in total during the latest reporting period.
Earlier
Sanofi files dengue vax in Aust
Pipeline: Sanofi has filed dengue fever vax Dengvaxia in Australia, seeking a licence to import the genetically modified live vaccine and approval from the TGA.
Amgen broadens CVD horizons
Reimbursement: Amgen says it will work with the PBAC to expand the scope of CVD drug Repatha after new clinical data showing it cut cardiovascular events.
AFT signs dry eye licence deal
Pipeline: AFT has signed an exclusive licensing deal to distribute German pharmaceutical Novaliq's evaporative dry eye treatment, Novotears, in Australia and New Zealand.
End risk-based regulation but protect our IP, says Swisse
Budget Wish List: CM giant Swisse is calling for stronger IP, a new pathway to the ARTG and Aussie diplomats to be equipped with CM expertise in a wide-ranging pre-2017/18 budget submission.
Debating Point
Resources in question as TGA modernises
Most areas of the pharmaceutical sector appear to agree that modernising the TGA is a good thing but how much pressure the new requirements will place on the regulator's resources remains an issue.
Approvals Action
Roche's new lung cancer drug approved
Roche's Alecensa has been approved for second-line treatment of ALK-positive advanced or metastatic NSCLC after Pfizer's Xalkori while Galderma has registered a higher dose form of acne treatment Epiduo.
Pipeline Monitor
Novartis sets sights on Pfizer's breast cancer lead
Novartis' new HR+/HER2- breast cancer medicine Kisqali has won first-line approval in the US, setting up a battle with Pfizer's Ibrance.
Special Report
Pharma sales reps' future - the next five years
Pharma is very good at training and deploying sales people in the field to sell brands. It's a model that has worked for many years. It's also one that's often said to be under threat, but is it really?
FREE Content
Events & Conferences
SEARCH NOW
Pharma in Focus Jobs
Ascott